JUBLIA Drug Patent Profile

When do Jublia patents expire, and what generic alternatives are available?

Jublia is a drug marketed by Bausch and is included in one NDA. There are eighteen patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-five patent family members in twenty-four countries.

The generic ingredient in JUBLIA is efinaconazole. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the efinaconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jublia

A generic version of JUBLIA was approved as efinaconazole by TEVA PHARMS USA on December 16^th, 2020.

Summary for JUBLIA

International Patents:	85
US Patents:	18
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	4
Patent Applications:	775
Drug Prices:	Drug price information for JUBLIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JUBLIA
What excipients (inactive ingredients) are in JUBLIA?	JUBLIA excipients list
DailyMed Link:	JUBLIA at DailyMed

See drug prices for JUBLIA

Recent Clinical Trials for JUBLIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dong-A ST Co., Ltd.	Phase 4
University of Alabama at Birmingham	Phase 4
University of Alabama at Birmingham	N/A

See all JUBLIA clinical trials

Pharmacology for JUBLIA

Drug Class

Azole Antifungal

Paragraph IV (Patent) Challenges for JUBLIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JUBLIA	Topical Solution	efinaconazole	10%	203567	19	2018-06-06

US Patents and Regulatory Information for JUBLIA

JUBLIA is protected by eighteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	7,214,506
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	9,302,009		Y
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	11,654,139
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	10,512,640
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	8,039,494
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	11,213,519

Expired US Patents for JUBLIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	7,214,506

International Patents for JUBLIA

See the table below for patents covering JUBLIA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	070083	COMPOSICIONES Y METODOS PARA TRATAR ENFERMEDADES DE LA UNA
Mexico	2010007230	COMPOSICIONES Y METODOS PARA TRATAR ENFERMEDADES DE LAS UÑAS. (COMPOSITIONS AND METHODS FOR TREATING DISEASES OF THE NAIL.)
European Patent Office	3052487
China	105683184
Israel	244850	תכשירים אפינאקאנאזול מיוצבים, ושימושים בהם (Stabilized efinaconazole compositions and uses thereof)
Malaysia	179756	STABILIZED EFINACONAZOLE FORMULATIONS

Supplementary Protection Certificates for JUBLIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3052487	122025000061	Germany		PRODUCT NAME: EFINACONAZOL; REGISTRATION NO/DATE: 7009117.00.00 20250821

JUBLIA (efinaconazole) Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

Jublia (efinaconazole) is a branded, topical antifungal for onychomycosis and competes in a shrinking, price-competitive category with frequent generic substitution for oral options. Its financial trajectory has been driven by (1) limited formulary leverage because it is a topical option for a chronic, visible condition; (2) sustained payer scrutiny and step edits; and (3) competitive intensity from both topical and oral antifungals as clinicians balance efficacy, safety, and total treatment cost.

What is Jublia’s market position in onychomycosis?

Jublia is positioned for patients with toenail fungus (onychomycosis), where topical therapy is used to avoid or reduce exposure to systemic antifungals. In practice, adoption depends on three variables:

1) Clinical outcomes vs. expectations
Onychomycosis has variable nail penetration and slow growth kinetics. Payers and prescribers typically expect outcome evidence that translates into durable clinical resolution, not just short-term fungal burden reduction.

2) Route-of-administration tradeoff
Jublia’s topical profile competes against oral agents that are often dosed as shorter, time-limited systemic courses. Even when oral agents have liver-related monitoring requirements, they can win when prescribers prioritize probability of clearance.

3) Formulary and step therapy pressure
Topical antifungals and payer policies frequently drive clinician behavior. Where payers require trials of lower-cost alternatives or restrict coverage by severity or nail involvement, market penetration slows.

How do category dynamics shape demand?

The onychomycosis drug market has structural characteristics that affect sales velocity and durability:

• Chronic disease with intermittent treatment patterns
  Many patients experience recurrence. However, they do not always seek care continuously, which makes demand lumpy and seasonal. Clinic visits rise with warm-weather exposure and higher cosmetic concern, but long-term payer restrictions and tolerance for watchful waiting can cap share.

• High price sensitivity at retail and pharmacy benefit levels
  As generics enter or shift price anchors, branded topical products face rapid loss of incremental demand unless they maintain strong net price and coverage.

• Low switching costs, high competition density
  Multiple therapeutic options exist in both topical and oral classes, making switching easy when formulary status changes. This compresses promotional ROI and increases sensitivity to payer exclusions.

What is Jublia’s financial trajectory in the context of branded declines?

Jublia’s financial pattern is consistent with a branded dermatology specialty product facing sustained price and coverage pressure. In this setting, sales tend to flatten and then decline as:

1) Net price erodes via payer contracting
Branded drug net price is pressured by rebate intensity, patient access programs that do not fully offset list-price erosion, and pharmacy benefit management decisions.

2) Generic competition for oral anchors influences total class behavior
Even when Jublia is not directly substitutable in a strict mechanistic sense, oral antifungal generics can pull prescribing away from topical strategies for eligible patients.

3) Indication and label breadth do not expand fast enough to outgrow competition
Growth typically requires either expanded eligible subgroups or a substantial change in clinical practice patterns. Without major label expansions, adoption depends on payer access and incremental guideline positioning.

What do key filings show about the commercial arc?

Jublia is marketed in the U.S. by Bausch Health, which has disclosed product and portfolio restructuring in periodic filings. In these disclosures, branded antifungal revenue is typically discussed within a broader dermatology and specialty portfolio where management prioritizes margin and cost discipline as sales mature.

• Bausch Health’s annual reporting frames product performance alongside broader portfolio actions (cost reductions, licensing and divestitures, and restructuring) tied to branded sales declines and competitive pricing pressure. (See Bausch Health Forms 10-K for commercial positioning and revenue line-item context.) [1]

How do pricing and access mechanics drive sales outcomes?

For topical antifungals like Jublia, payer access decisions can determine whether a patient starts and completes therapy. Typical mechanisms include:

• Prior authorization and formulary tiering
  Coverage can require documentation of disease confirmation and extent. Step edits often require trial of older or lower-cost topical therapy.

• Patient copay steering and coupon dependency
  Net price is heavily influenced by copay support and rebate structures. When payers renegotiate or restrict patient eligibility for assistance programs, effective demand can drop even if list price remains stable.

• Pharmacy channel effects
  Mail-order and large PBM networks can negotiate discounts that accelerate list-to-net compression for branded drugs.

The net result is that branded topical antifungals frequently show a sales curve where growth peaks on launch-driven awareness and then transitions to a slower decline as access tightens.

Competitive landscape: what shifts market share away from Jublia?

Jublia competes across three lines of pressure:

1) Topical alternatives
Other topical antifungal products and devices can win on coverage status, prescriber comfort, and patient preference.

2) Oral therapy choices, including generic penetration
Generic oral antifungals expand price-competitive options for patients who can tolerate systemic treatment and for whom physicians want higher probability of clearance.

3) Non-pharmacologic and adherence barriers
Nail growth is slow. Patients may stop due to cost, time-to-response, and cosmetic expectations, which opens the door for multiple re-challenges with competing products.

What are the key value drivers for Jublia’s commercial outlook?

For an antifungal topical brand, value drivers are operational and payer-led:

• Net price stability versus discounting pressure
• Continuity of payer coverage in dermatology and podiatry segments
• Prescriber retention and patient adherence support
• Any label or guideline shift that expands eligibility or increases perceived value

Jublia’s future trajectory is therefore less about manufacturing scale and more about access, contracting, and evidence interpretation in routine care.

---

Market Metrics Snapshot (U.S.)

Dimension	Jublia (efinaconazole topical)	Competitive pressure
Drug type	Branded topical antifungal	Dense topical and oral options
Demand profile	Chronic condition, adherence-dependent	Recurrence and lumpy diagnosis patterns
Pricing risk	High list-to-net compression risk	PBM contracting, rebate pressure
Access risk	PA and step edits common in payers	Coverage restrictions reduce initiation
Substitution risk	Oral generics can redirect prescribing	Easy switching when formularies change

Regulatory context: Jublia is an approved prescription topical drug for onychomycosis. (FDA product/regulatory record.) [2]

---

How does the product fit into Bausch Health’s broader financial trajectory?

Bausch Health’s public filings show the company managing a diversified portfolio with ongoing rationalization and cost control. Branded specialty revenue performance is typically impacted by mature-product declines, competitive entry dynamics, and negotiated net price outcomes. Jublia’s sales therefore behave as a mature-branded asset under a broader capital allocation framework. (Bausch Health annual reporting and segment/product discussion.) [1]

---

Key Takeaways

• Jublia’s market dynamics are dominated by payer access pressure, price-to-net erosion, and high substitution within antifungal therapy options.
• The financial trajectory aligns with mature branded specialty dermatology: peak awareness-driven uptake followed by flattening and decline as coverage tightens.
• Competitive dynamics shift share through oral generic anchors and easy switching in both podiatry and dermatology prescribing workflows.
• The most important commercial levers are net price stability, prior authorization resilience, and adherence support, not manufacturing scale or incremental labeling absent major clinical practice changes.

---

FAQs

1) Is Jublia primarily affected by topical competition or oral competition?
Both. Topical competitors affect coverage and prescribing choices, while oral generics influence whether clinicians choose systemic therapy for eligible patients.

2) What most directly changes Jublia’s sales month-to-month?
Payer authorization and formulary status shifts, plus patient copay outcomes that affect initiation and completion rates.

3) Does onychomycosis create durable demand for Jublia?
It creates recurring clinical encounters, but recurrence does not guarantee repeat use of the same branded product due to switchability and access constraints.

4) How do net price mechanics impact branded topical antifungals?
Rebates and contracting pressure reduce effective revenue per unit; sales can decline even if retail demand holds.

5) How should investors interpret Jublia within Bausch Health reporting?
As a mature branded specialty asset sensitive to net price erosion, competitive intensity, and payer access, with performance embedded in broader portfolio-level decisions.

---

References

[1] Bausch Health Companies Inc. Form 10-K (latest available annual filing). U.S. Securities and Exchange Commission.
[2] U.S. Food and Drug Administration. Jublia (efinaconazole) product/regulatory information and labeling.